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a  b  s  t  r  a  c  t
Antibiotic  therapy  for  complicated  intra-abdominal  infections  (cIAIs)  should  provide  broad-spectrum
coverage  both  Gram-positive  and  Gram-negative  microorganisms.  The  PROMISE  study  compared  the
clinical  and  bacteriological  efﬁcacy  and  safety  of  moxiﬂoxacin  versus  ertapenem  for  the  treatment  of
cIAIs.  This  randomised,  prospective,  double-dummy,  double-blind,  multicentre  trial  was designed  as  a
non-inferiority  study.  The  safety  and  efﬁcacy  of 5–14 days  of daily  intravenous  moxiﬂoxacin  (400  mg) or
ertapenem  (1  g)  were  compared  in  patients  with  cIAIs  requiring  surgery  and  parenteral  antibiotic  therapy.
The  primary  and  secondary  endpoints  included  clinical  and  bacteriological  responses  at  21–28 days  after
the  end  of  treatment  (TOC),  respectively.  Of 830 enrolled  patients,  699  were  efﬁcacy  valid.  Moxiﬂoxacin
was  non-inferior  to  ertapenem  regarding  clinical  success  [89.5%  (315/352)  versus  93.4%  (324/347);  95%
conﬁdence  interval  (CI)  −7.9%, 0.4%].  There  were  no  signiﬁcant  differences  between  groups  for  any  of  the
primary  causes  or types  of  cIAI regarding  clinical  response.  Bacteriological  success  was achieved  in  86.5%
(257/297)  of  moxiﬂoxacin-treated  patients  and  90.2%  (249/276)  of ertapenem-treated  patients  (95%  CI
−9.0%,  1.5%).  There  were  no  major  differences  between  groups  regarding  the frequency  or  types  of  orga-
nisms  eradicated.  The  incidence  of  adverse  events  (AEs)  was higher  with  moxiﬂoxacin  than  ertapenem
(P  =  0.039),  however  a similar  number  of  drug-related  AEs  was  seen  in each  group  (P =  1.000).  Wound
infections,  nausea  and  increased  lipase  were  the  most  commonly  reported  AEs  with  both  agents.  The
results  show  that moxiﬂoxacin  is a valuable  treatment  option  for a range  of  community-acquired  cIAIs
with  mild-to-moderate  severity  [Clinical  Trials.gov  Identiﬁer:  NCT00492726].
nd th  © 2012 Elsevier B.V. a    
. IntroductionComplicated intra-abdominal infections (cIAIs) extend beyond
he hollow viscus of origin into the peritoneal cavity and are
ssociated with localised or generalised peritonitis or abscess
 Previous presentations of data: clinical and microbiological data from the
ROMISE  study have been presented at the 20th European Congress of Clinical
icrobiology  and Infectious Diseases (ECCMID), 10–13 April 2010, Vienna, Austria,
nd the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
ICAAC),  12–15 September 2010, Boston, MA;  and peritonitis data have been pre-
ented at the 24th European Congress of Surgical Infection Society, 25–28 May  2011,
eon, Spain.
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ax: +32 93 32 49 95.
E-mail  address: Jan.DeWaele@UGent.be (J.J. De Waele).
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Open accese International Society of Chemotherapy.     
formation [1]. Patient stabilisation and surgical source control in
cIAI management are crucial [1]. Furthermore, broad-spectrum
antibiotic therapy against causative bacteria is essential [1]. Moxi-
ﬂoxacin, a ﬂuoroquinolone with good in vitro activity against most
causative organisms in cIAIs [2,3], penetrates well into inﬂamed
gastrointestinal tissues [4–7] and is a reliable treatment option
for cIAIs [8–10]. Ertapenem is also active against a range of intra-
abdominal pathogens [11] and has demonstrated clinical efﬁcacy
in cIAIs [12,13]. Both agents can be administered once daily in
intravenous (i.v.) formulations [14,15] and are recommended by
the Infectious Diseases Society of America (IDSA) for the treatment
of mild-to-moderate community-acquired cIAIs in adults [1].
This  study (PROMISE, Clinical Trials.gov Identiﬁer
Open access under CC BY-NC-ND license.NCT00492726) compared the clinical and bacteriological efﬁcacy
and safety of moxiﬂoxacin versus ertapenem for the treatment
of cIAIs. A non-inferiority design was selected for this ran-
domised clinical trial because the study drugs have shown similar
s under CC BY-NC-ND license. 
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fﬁcacy to standard -lactam-based antimicrobial regimens
8–10,12,13,16].
. Methods
.1. Study design
This  prospective, randomised, double-dummy, double-blind,
ulticentre, non-inferiority study compared the safety and efﬁ-
acy of 5–14 days of i.v. moxiﬂoxacin or ertapenem in patients with
IAI requiring surgery and parenteral antibiotic therapy. Patients
ere evaluated: at pre-treatment (within 24 h before initiation of
tudy drug); during treatment (daily and complete evaluation on
ay 5 ± 1); at the end of treatment (EOT), between Day 5 and Day
4; and at the test-of-cure (TOC) visit, between 21–28 days after
OT.
.2. Study treatments
Patients  received once-daily i.v. therapy with either 400 mg
f moxiﬂoxacin [14] (Avelox®; Bayer Healthcare AG, Leverkusen,
ermany) or 1 g of ertapenem [15] (Invanz®; Merck, Haar,
ermany) in a double-blind manner. Patients in the moxiﬂoxacin
rm received placebo for 30 min  immediately followed by moxi-
oxacin 400 mg  in 250 mL  over 60 min  every 24 h for 5–14 days.
atients in the ertapenem arm received ertapenem 1.0 g in 50 mL
ver 30 min  followed by placebo for 60 min  every 24 h for 5–14
ays.
.3. Treatment allocation and blinding
Patients were randomly and equally assigned to treatment
roups. The randomisation code was generated by the Department
f Biometry at Bayer HealthCare AG. Investigators called an inter-
ctive voice response system for treatment group assignment.
.4.  Patients: inclusion criteria
Patients  were ≥18 years with a conﬁrmed or suspected cIAI
equiring hospitalisation and i.v. antibiotic therapy (for 5–14 days).
or patients with conﬁrmed cIAI, laparotomy or laparoscopy was
erformed within 24 h prior to enrolment, revealing (i) gross peri-
oneal inﬂammation with purulent exudate, (ii) intra-abdominal
bscess or (iii) macroscopic intestinal perforation with localised
r diffuse peritonitis. Patients with suspected cIAI were required
i) to display radiological evidence of gastrointestinal perforation
r intra-abdominal abscess, (ii) to have more than one abdominal
avity-related symptom (e.g. nausea, vomiting, distension or pain)
asting for ≥24 h and tenderness (with or without rebound), invol-
ntary guarding, absent or diminished bowel sounds, or abdominal
all rigidity (at least one sign) and systemic inﬂammatory response
yndrome criteria [at least two of the following signs: increased
ody temperature (>38.3 ◦C rectal or tympanic membrane, >37.8 ◦C
ral or >37.3 ◦C axillary), increased heart rate (>90 beats/min),
ncreased respiratory rate (>20 breaths/min) and white blood
ell count >12 000 cells/mm3 or <4000 cells/mm3] and (iii) to be
cheduled for laparotomy or laparoscopy within 24 h of enrolment.
Demographic data, pre-therapy systemic antibiotic use, the type
nd mean duration of initial surgery, and the origin, primary cause
nd type of infection were recorded at baseline. Disease sever-
ty was assessed using the Acute Physiology and Chronic Health
valuation (APACHE) score, Physiological and Operative Severity
core for the Enumeration of Mortality and Morbidity (POSSUM)
nd Mannheim Peritonitis Index (MPI). Localised peritonitis was
eﬁned as peritonitis limited to one quadrant and diffuse peritoni-
is as peritonitis in more than two quadrants.ntimicrobial Agents 41 (2013) 57– 64
2.5.  Patients: exclusion criteria
Exclusion  criteria included: hypersensitivity to study drugs;
pregnancy or breastfeeding; ﬂuoroquinolone-related tendon
disorder; clinically relevant cardiac conditions or QT interval-
prolonging drugs; severe hepatic insufﬁciency (Child–Pugh C);
creatinine clearance ≤30 mL/min/1.73 m2; need for other sys-
temic antibacterial therapy or use for >24 h within 7 days prior
to randomisation; indwelling peritoneal catheter or vascular
shunt; pre-existing ascites and presumed spontaneous bacterial
peritonitis; perforation of the stomach or duodenum (duration
<24 h); small or large bowel perforation due to trauma lasting
<12 h; all pancreatic processes or an IAI secondary to pancre-
atitis; liver or splenic abscess; transmural bowel ischaemia or
necrosis without perforation or established peritonitis or abscess;
non-perforated cholecystitis; acute cholangitis; non-perforated
appendicitis; requirement for antibiotic irrigations of the abdom-
inal cavity or surgical wound; treatment with ‘open abdomen’ or
marsupialisation, or multiple planned relaparotomies; infections
of the female genital tract; perinephric infections; septic shock
requiring vasopressors (>12 h); known underlying fatal disease
(death expected within 6 months); immunological compromise
(including drug-induced); and body mass index ≥45 kg/m2.
2.6. Primary and secondary endpoints
The primary endpoint was  clinical success at 21–28 days after
EOT (TOC visit). Clinical efﬁcacy at TOC was clinical success,
relapse or indeterminate. Secondary endpoints included clinical
and bacteriological response at EOT (Days 5–14) and clinical and
bacteriological responses at the TOC visit in patients with a bacteri-
ologically documented cIAI. Bacteriological responses were success
(eradication or presumed eradication) or failure (persistence or
presumed persistence).
Safety  parameters were evaluated based on physical exami-
nations, reported adverse events (AEs), vital signs and laboratory
results.
2.7. Microbiological assessment
Peritoneal  and abscess ﬂuids were sampled at the time
of surgery. Minimum inhibitory concentrations (MICs) of test
antibiotics were determined for aerobic organisms according to
Clinical and Laboratory Standards Institute (CLSI) broth microdi-
lution methodology [17]. Anaerobes were tested by agar dilution
according to CLSI guidelines [17]. Extended-spectrum -lactamase
(ESBL)-producing Enterobacteriaceae species were identiﬁed by
double disk diffusion test [17]. ESBL production was  con-
ﬁrmed where the initial broth microdilution testing indicated a
MIC  ≥ 1 mg/L for both ceftriaxone and ceftazidime. All microbio-
logical tests were performed at the Central Laboratory (Euroﬁns
Medinet, Plaisir, France).
2.8.  Patient populations
Per-protocol (PP): patients diagnosed with a cIAI during surgery
and managed within 24 h of enrolment and without concomitant
antibacterial agent. For treatment failure, patients received the
study drug for ≥3 days; for clinical success, patients received the
study drug for ≥5 days with documented study medication com-
pliance of ≥80% and no protocol violations inﬂuencing treatment
efﬁcacy.
Intention-to-treat (ITT) (safety analysis): all randomised
patients with at least one dose of study drug and more than one
observation for safety or efﬁcacy after receiving study medication.
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n = 804
n = 798
n = 573
n = 699
Enrolled
(n = 830 )
Intent-to -treat (ITT, safety -valid) 
population
(n = 390 )
Per-protocol (PP, efficacy -valid) population
(n = 352 )
Per-protocol (PP, efficacy -valid) population
(n = 347 )
Microbiologically valid population (MBV)
(n = 297 )†
Microbiologically valid population (MBV)
(n = 276 )†
Moxifloxacin randomised
(n = 410 )
Ertapenem randomised
 (n = 394 )
ITT with causative 
organisms
(n = 340 )
ITT with causative 
organisms
(n = 308 )
Exclusions prior to randomisation
Protocol violations (n = 17 )
Technical/protocol problems (n = 4 )
Died before randomisation (n = 1 )
Withdrew consent (n = 2)
Switched to commercial drug (n = 1 )
Investigator decision (n = 1 )
Exclusions from ITT population (n = 2  patients)*
Not treated with study  drug  (n = 2)
Consent withdrawn (n = 2)
Exclusions from ITT population (n = 4 patients)*
Violation of in/exclusion criteria (n = 3)
Not treated with study drug (n = 4)
Consent withdrawn (n = 1)
Exclusions from PP population (n = 58  patients)*
Violation of in/exclusion criteria (n = 17)
Not treated with study  drug (n = 2)
Insufficient duration of  therapy (n = 12)
Violation of time schedule ( n = 16)
Consent  withdrawn ( n = 7)
Essential data missing or  invalid ( n = 30)
Use of prohibited concomitant medication (n = 9)
Exclusions from PP population (n = 47 patients)*
Violation of in/exclusion criteria (n = 15 )
Not treated with study drug (n = 4)
Insufficient duration of therapy (n = 7)
Violation of time schedule (n = 13)
Consent withdrawn (n = 3)
Essential data missing or invalid (n = 25)
Use of prohibited concomitant medication (n = 14 )
Exclusions from MBV population (n = 113  patients)*
No causative organism  pre-therapy (n = 55)
Not valid for  Safety/ITT (n = 2)
Valid for ITT but not valid for PP ( n = 56)
Exclusions from MBV population (n = 113 patients)*
No causative organism pre-therapy (n = 71 )
Not valid for Safety/ITT (n = 4)
Valid for ITT but not valid for PP (n = 43)
Intent-to -treat (ITT, safety -valid) 
population
(n = 408 )
Fig. 1. Patient disposition and study populations. *Individual patients could have more than one reason for exclusion. †Includes one patient with positive blood culture and
n crobio
a
o
c
2
i
ﬁ
q
ﬁ
a
w
T
t
t
c
c
t
p
u
D
segative intra-abdominal culture. ITT, intention-to-treat; PP per-protocol; MBV, mi
Microbiologically valid (MBV) and ITT with causative organisms:
ll PP and ITT patients, respectively, with at least one causative
rganism identiﬁed from a baseline intra-abdominal and/or blood
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.9.  Data validation, sample size and statistical analysis
To  ensure that only patients with adequate source control were
ncluded in the analysis, a medical review panel checked the suf-
ciency of initial surgery in a blinded fashion. Information was
ueried where necessary with the investigator; patients with insuf-
cient surgery were excluded from the PP analysis.
Sample size estimation was based on the primary efﬁcacy vari-
ble. Assuming a validity rate of approximately 80%, 402 patients
ere required per arm to give a total population of at least 804.
he primary aim of the study was to reject the null hypothesis
hat 5–14 days of moxiﬂoxacin therapy was >10% less effective
han 5–14 days of ertapenem therapy. Moxiﬂoxacin was deemed
linically non-inferior to ertapenem if the lower limit of the 95%
onﬁdence interval (CI) was more than −10%, as used in registra-
ion studies for cIAIs. All statistical tests were two-sided and were
erformed at the 0.05 signiﬁcance level. Groups were compared
sing the Cochran–Mantel–Haenszel point estimate and 95% CIs.
escriptive analyses were performed on secondary variables and
ubgroups.logically valid.
3. Results
3.1. Patient disposition
A  total of 830 patients were enrolled in 52 centres in 14
countries across Europe, South America and South Africa. Of  the
enrolled patients, 804 were randomised (Fig. 1): Baltic countries,
259 (32.2%); Eastern Europe, 188 (23.4%); Western Europe, 132
(16.4%); South America, 127 (15.8%) and South Africa, 98 (12.2%).
For the primary efﬁcacy endpoint, 352 moxiﬂoxacin-treated and
347 ertapenem-treated patients were analysed.
3.2. Patient demographics and characteristics of complicated
intra-abdominal infections
There  were no signiﬁcant differences between groups for
various baseline patient characteristics (Table 1). Most PP
patients (668/699; 95.6%) had community-acquired infection.
The most common causes of cIAIs were acute appendicitis
and perforated ulcer, and most patients presented with dif-
fuse peritonitis. There were no signiﬁcant differences between
treatment groups for the type or cause of infection or dis-
ease severity at baseline. Approximately 70% of patients received
antibiotic therapy for ≤24 h in the previous 7 days. Both mox-
iﬂoxacin and ertapenem were infused for approximately 7 days
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Table 1
Patient demographics and characteristics at baseline (per-protocol population).
Characteristic Moxiﬂoxacin (N = 352) Ertapenem (N = 347) P-valuea
Sex male [n (%)] 218 (61.9) 231 (66.6) 0.167
Age mean ± S.D. (years) 46.7 (17.8) 46.1 (17.7) 0.579
BMI mean ± S.D. (kg/m2) 26.0 (4.7) 25.8 (4.6) 0.387
Temperatureb >38.3 ◦C [n (%)] 212 (60.2) 201 (57.9) 0.394
WBC count mean ± S.D. (×109/L) 13.3 (5.1) 13.5 (5.4) 0.522
CRP mean ± S.D. (mg/dL) 18.9 (11.3) 17.2 (11.2) 0.052
Procalcitonin mean ± S.D. (ng/mL) 5.0 (19.3) 5.3 (17.9) 0.874
Initial surgery
Laparotomy [n (%)] 312 (88.6)  315 (90.8) 0.294
Laparoscopy [n (%)] 40 (11.4) 31 (8.9)c
Duration mean ± S.D. (min) 81.0 (41.5) 80.8 (40.0) 0.939
Severity of disease at baseline (mean ± S.D.)
APACHE II score 6.9 (4.3) 6.8 (4.6) 0.646
POSSUM score 35.3 (7.8) 34.9 (7.4) 0.411
Mannheim Peritonitis Index 19.1 (7.0) 19.0 (7.3) 0.928
Origin of infectiond 0.601
Community-acquired [n (%)] 334 (94.9) 334 (96.3)
Hospital-acquired [n (%)] 16 (4.5) 11 (3.2)
Primary type of infection [n (%)]
Single abscess 69 (19.6) 64 (18.4) 0.541
Multiple abscesses 2 (0.6) 2 (0.6) 1.000 c
Localised peritonitise 100 (28.4) 96 (27.7) 0.798
Diffuse peritonitisf 181 (51.4) 185 (53.3) 0.473
Primary cause of infection [n (%)] 0.492
Cholecystitis 33 (9.4) 32 (9.2)
Diverticulitis 29 (8.2) 16 (4.6)
Trauma 19 (5.4) 23 (6.6)
Tumour 13 (3.7) 13 (3.7)
Previous surgery 15 (4.3) 9 (2.6)
Acute appendicitis 172 (48.9) 176 (50.7)
Perforated ulcer 53 (15.1) 55 (15.9)
Otherg 18 (5.1) 23 (6.6)
Pre-therapy systemic antibiotic use [n (%)] 243 (69.0) 246 (70.9) 0.546
S.D., standard deviation; BMI, body mass index; WBC, white blood cell; CRP, C-reactive protein; APACHE, Acute Physiology and Chronic Health Evaluation; POSSUM,
Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity.
a Cochran–Mantel–Haenszel test.
b Rectal or tympanic membrane.
c Information missing in one patient.
d Information missing in two patients in each group.
e Deﬁned as peritonitis limited to one quadrant.
f Deﬁned as peritonitis in two  or more quadrants.
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Clinical  success at TOC in the PP population was  similarly high
in both groups [moxiﬂoxacin 315/352 (89.5%) versus ertapenem
324/347 (93.4%)] (Fig. 2). Clinical success with moxiﬂoxacin was
non-inferior to ertapenem, with the lower limit of the 95% CI of
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Moxifloxacin Ertapenem
324/347315/352
95% CI: –7.9, 0.4
334/408 339/390
95% CI:  –9.9, 0.0g Single intra-abdominal abscess, perforation unrelated to trauma of small bowel, b
atrogenic, congenital anatomical abnormalities, idiopathic, catheterisation, empye
adiation enteritis, and sigmoiditis.
moxiﬂoxacin 7.0 ± 2.5 days and ertapenem 6.8 ± 2.2 days, respec-
ively).
.3. Baseline bacteriology
A  total of 1927 microorganisms were isolated from the
eritoneal cavity of 571 MBV  patients at the time of surgery.
n addition, 13 patients (moxiﬂoxacin 10, ertapenem 3) had
acteraemia. Most MBV  patients had polymicrobial infections
moxiﬂoxacin 250/296 (84.5%), ertapenem 231/275 (84.0%)].
mong the Gram-negative organisms, Escherichia coli (mox-
ﬂoxacin 266, ertapenem 240) was the predominant aerobic
athogen, and Bacteroides fragilis (moxiﬂoxacin 90, ertapenem
5) and Bacteroides thetaiotaomicron (moxiﬂoxacin 45, ertapenem
4) were the most common anaerobes. Of the 13 ESBL-producing
athogens identiﬁed, 9 were E. coli (moxiﬂoxacin 2, ertapenem 7),
 were Klebsiella pneumoniae (moxiﬂoxacin 1, ertapenem 2) and 1
as Serratia marcescens (ertapenem group).
Streptococcus anginosus (moxiﬂoxacin 74, ertapenem 69) and
treptococcus constellatus (moxiﬂoxacin 51, ertapenem 42) were
he most commonly isolated Gram-positive aerobes. Enterococ-
us faecalis (moxiﬂoxacin 35, ertapenem 35), Enterococcus faecium
moxiﬂoxacin 24, ertapenem 19) and Enterococcus avium (moxi-
oxacin 16, ertapenem 21) were also isolated. obstruction, malignancy hernia, adhesion, peritonitis, Crohn’s disease, foreign body,
llbladder stones, ischaemia, paralytic ileus, rupture, inﬂammation and perforation,
3.4.  Overall clinical efﬁcacy0
PP ITT
Fig. 2. Overall clinical efﬁcacy in the per-protocol (PP) and intention-to-treat (ITT)
populations. CI, conﬁdence interval.
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Table 2
Clinical success rate by type and cause of infection (per-protocol population).
Clinical success [n/N (% of patients)]a P-valueb
Moxiﬂoxacin Ertapenem
Primary type of infection
Single  abscess 59/69 (85.5) 59/64 (92.2) 0.290
Multiple abscesses 1/2 (50.0) 1/2 (50.0) 1.000
Localised peritonitisc 93/100 (93.0) 90/96 (93.8) 0.721
Diffuse peritonitisd 162/181 (89.5) 174/185 (94.1) 0.192
Primary cause of infection
Cholecystitis  33/33 (100) 31/32 (96.9) 0.283
Diverticulitis 28/29 (96.6) 15/16 (93.8) 0.355
Trauma 16/19 (84.2) 21/23 (91.3) 0.453
Tumour 8/13 (61.5) 11/13 (84.6) 0.438
Previous surgery 9/15 (60.0) 6/9 (66.7) 0.944
Acute appendicitis 155/172 (90.1) 167/176 (94.9) 0.090
Perforated ulcer 51/53 (96.2) 54/55 (98.2) 0.710
Othere 15/18 (83.3) 19/23 (82.6) 0.938
a Clinical success: resolution/improvement of clinical signs/symptoms of the
infection  and antibiotic therapy no longer required, plus no wound infections
requiring  systemic antibiotic treatment based on investigator judgement; other-
wise relapse: reappearance of signs/symptoms of the original infection, or wound
infection requiring further systemic treatment; or indeterminate: clinical evaluation
not possible.
b Cochran–Mantel–Haenszel test.
c Deﬁned as peritonitis limited to one quadrant.
d Deﬁned as peritonitis in two or more quadrants.
e Single intra-abdominal abscess, perforation unrelated to trauma of small
bowel,  bowel obstruction, malignancy, hernia, adhesion, peritonitis, Crohn’s dis-
ease, foreign body, iatrogenic, congenital anatomical abnormalities, idiopathic,
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Matheterisation,  empyema, gallbladder stones, ischaemia, paralytic ileus, rupture,
nﬂammation  and perforation, radiation enteritis, and sigmoiditis.
7.9% (Fig. 2). The high clinical success rates in the ITT population
Fig. 2) [moxiﬂoxacin 334/408 (81.9%) versus ertapenem 339/390
86.9%)], with no signiﬁcant between-group differences (P = 0.052),
urther supports this. In the PP population, clinical success rates at
OT were high in both groups [moxiﬂoxacin 328/352 (93.2%) versus
rtapenem 330/347 (95.1%)], with no signiﬁcant between-group
ifferences (95% CI −5.3%, 1.7%; P = 0.314).
.5. Clinical efﬁcacy by type or cause of infection
Clinical success rates were high and were not signiﬁcantly
ifferent for the two treatment groups in patients with single
bscesses, localised peritonitis or diffuse peritonitis (Table 2). There
ere only a few patients with multiple abscesses (n = 4) to deter-
ine relative efﬁcacy of the two antimicrobial agents.
Clinical success rates were the highest in both treatment arms
or patients with community-acquired infections (cholecystitis,
ong-standing perforated ulcer, diverticulitis, perforated gastroin-
estinal tract after trauma and appendicitis) (Table 2). Cure rates
n both groups were lower in patients with nosocomial infections,
peciﬁcally following surgery, although numbers of patients in this
able 3
verall bacteriological success and pre-therapy minimum inhibitory concentrations (MIC
avity at baseline (microbiologically valid population).
Organism Bacteriological success [n/N (% o
Moxiﬂoxacin 
Gram-positive aerobes 259/311 (83.3) 
Streptococcus anginosus 60/74 (81.1) 
Streptococcus constellatus 43/51 (84.3) 
Gram-negative fermentative rods 382/442 (86.4) 
Non-ESBL-producing Escherichia coli 232/264 (87.9) 
Gram-negative anaerobic rods 202/247 (81.8) 
Bacteroides  fragilis 71/90  (78.9) 
Bacteroides  thetaiotaomicron 37/45 (82.2) 
IC50/90, MICs for 50% and 90% of the organisms, respectively; ESBL, extended-spectrum Fig. 3. Overall bacteriological efﬁcacy in the microbiologically valid (MBV) and
intention-to-treat (ITT) with causative organism populations. CI, conﬁdence inter-
val.
group were low (moxiﬂoxacin 15, ertapenem 9). There were no sig-
niﬁcant between-group differences for any of the primary causes
of infection.
3.6. Clinical efﬁcacy by pathogen
Clinical  success rates were high for both moxiﬂoxacin and
ertapenem for each of the ﬁve most commonly isolated organisms
and across a range of MICs (Table 3).
3.7. Bacteriological efﬁcacy
Bacteriological success rates at TOC in the MBV  and ITT popula-
tions with causative organisms were high for both moxiﬂoxacin
and ertapenem, respectively (Fig. 3). In both treatment groups,
the bacteriological success rate at TOC was higher in patients
with monomicrobial infections [moxiﬂoxacin 44/46 (95.7%) versus
ertapenem 43/44 (97.7%)] than in patients with polymicro-
bial infections [moxiﬂoxacin 212/250 (84.8%) versus ertapenem
205/231 (88.7%)].
Bacteriological success rates were comparable between groups
in patients with single abscesses (moxiﬂoxacin 82.8% versus
ertapenem 88.1%), localised peritonitis (moxiﬂoxacin 88.1% versus
ertapenem 93.4%) and diffuse peritonitis (moxiﬂoxacin 87.2%
versus ertapenem 89.9%). There were no signiﬁcant differences
between moxiﬂoxacin and ertapenem for any type of infection.3.8.  Safety and tolerability
Treatment-emergent AEs were experienced by >50% of patients
in each group, with signiﬁcantly more patients in the moxiﬂoxacin
s) for the ﬁve most commonly isolated organisms (≥2%) from the intra-abdominal
f organisms)] MIC50/90 (mg/L)
Ertapenem Moxiﬂoxacin Ertapenem
244/275 (88.7)
62/69 (89.9) 0.120/0.250 0.120/0.250
40/42 (95.2) 0.120/0.120 0.250/0.500
336/375 (89.6)
209/233 (89.7) 0.060/0.500 ≤0.015/≤0.015
215/240 (89.6)
87/95 (91.6) 0.500/4.000 0.120/0.500
51/54 (94.4) 2.000/4.000 1.000/1.000
-lactamase.
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Table 4
Incidence of treatment-emergent adverse events (AEs)a by patient (intent-to-treat/safety population).
Event Moxiﬂoxacin (N = 408) [n (%)] Ertapenem (N = 390) [n (%)] P-valueb
Any AE 239 (58.6) 200 (51.3) 0.039
Drug-related AEs occurring in more than ﬁve patients in either treatment group
Any 77 (18.9) 74 (19.0) 1.000
Gastrointestinal disorders 19 (4.7) 12 (3.1) 0.275
Nausea 12 (2.9) 3 (0.8)
Laboratory investigations 37 (9.1) 38 (9.7) 0.809
ALT increase 10 (2.5) 8 (2.1)
AST increase 7 (1.7) 7 (1.8)
Blood amylase increase 6 (1.5)  8 (2.1)
GGT increase 13 (3.2) 16 (4.1)
Lipase increase 14 (3.4) 18 (4.6)
Skin or subcutaneous 4 (1.0) 8 (2.1) 0.254
Vascular disorders 8 (2.0) 6 (1.5) 0.789
Phlebitis 6 (1.5) 5 (1.3)
Serious AEs 60 (14.7) 48 (12.3) 0.352
Drug-related serious AEs 9  (2.2) 6 (1.5) 0.605
Premature terminations due to AEs 11 (2.7) 6 (1.5) 0.329
Deaths 22 (5.4)c 12 (3.1) 0.117
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, -glutamyl transpeptidase; EOT, end of treatment.
a Non-serious AEs were reported from the ﬁrst application of study medication up to ≤7 days after EOT, and serious AEs up to ≤21 days after EOT for patients without
alternative therapy.
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sb Fisher’s exact test for treatment-emergent events versus non-treatment-emerg
c Includes two deaths from events not considered treatment-emergent (one mili
ay  1 and one cardiac arrest starting 29 days after EOT leading to death the same d
roup (239/408; 58.6%) than the ertapenem group (200/390; 51.3%)
P = 0.039) (Table 4).
The most commonly reported AEs in both groups were wound
nfections, nausea and increased lipase. Wound infections and nau-
ea occurred in more moxiﬂoxacin-treated than ertapenem-treated
atients (12% versus 7% and 8% versus 4%, respectively). Most
ound infections were superﬁcial in terms of tissue depth.
There  were no signiﬁcant differences between groups regarding
rug-related AEs, serious AEs, drug-related serious AEs, premature
ermination of treatment due to AEs or deaths. The predominant
rug-related AEs were in the gastrointestinal disorders and labora-
ory investigations categories.
There were 22 deaths in the moxiﬂoxacin group and 12 in the
rtapenem group (P = 0.117). Four deaths occurred during treat-
ent (moxiﬂoxacin 3, ertapenem 1) and 30 deaths occurred after
OT (moxiﬂoxacin 19, ertapenem 11). No deaths in the moxi-
oxacin group were considered to be treatment-related, whereas
ne death in the ertapenem group was considered treatment-
elated.
There was no evidence of any treatment effect on the inci-
ence of hepatic events. The number of patients with increased
ransaminases was similar in both groups, and no patients in
ither group had an AE that was a surrogate of arrhythmia. One
atient in each group experienced Clostridium difﬁcile colitis, with
he moxiﬂoxacin-treated patient permanently discontinuing treat-
ent.
. Discussion
PROMISE is the largest study of antimicrobials performed in cIAI
atients and the fourth trial showing that moxiﬂoxacin is clinically
nd bacteriologically comparable with other antibiotics in this
ndication. Previous studies compared moxiﬂoxacin monotherapy
ith third-generation cephalosporin plus metronidazole or
-lactam/-lactamase inhibitors [9,10]. This is the ﬁrst compari-
on of once-daily monotherapy with moxiﬂoxacin or a carbapenem
n community-acquired cIAIs [1,18].This study demonstrated that moxiﬂoxacin was clinically and
acteriologically non-inferior to ertapenem in treating cIAIs, with
igh clinical efﬁcacy (85–90%) for both agents across most cIAI
ubtypes. These ﬁndings were consistent with those of previousents or no events.
berculosis diagnosed the day before start of study medication resulting in death at
randomised controlled trials comparing the clinical and bacteri-
ological  efﬁcacy of moxiﬂoxacin [8–10] or ertapenem [12,13]. In
addition to providing similar clinical efﬁcacy to a number of com-
parators, both drugs provide the advantage of once-daily dosing
[14,15], which may  be an important differentiator regarding ease
of use.
Antibiotic therapy should be initiated in patients with a con-
ﬁrmed or highly suspected diagnosis of intra-abdominal infection
and should reach a high plasma level that is effective against
potential bacterial contamination from the surgical intervention
[1]. In addition to antibiotic therapy, surgical source control is
pivotal. Without adequate drainage or debridement and restoration
of anatomic structures, antibiotic therapy will be ineffective or will
be administered for a prolonged duration and may  unnecessarily
lead to increased antimicrobial resistance [19].
In equivalence or non-inferiority studies, similar conclusions
both from ITT and PP analyses are required for robust interpre-
tation of results. This requirement was met  in this study as the
clinical results of the PP, ITT and MBV  population analyses showed
the same overall trend (because the lower limit of the 95% CI for all
these populations was  greater than −10%); although a numerical
difference and a trend towards signiﬁcant difference in disfavour
of moxiﬂoxacin was seen in the ITT population, explained by higher
number of missing/indeterminate evaluations that were not surro-
gates of clinical failure.
The  outcome of antimicrobial treatment in cIAIs is dependent
on the type and virulence of the infecting organisms. The most
commonly isolated baseline pathogens were Gram-negative
non-ESBL-producing E. coli (497 isolates) and the anaerobe B.
fragilis (185 isolates). There are reports of increasing resistance
of B. fragilis isolates to available quinolones [20,21]. In this study,
clinical or bacteriological outcomes were not affected by reduced
sensitivity to moxiﬂoxacin in a few isolates. Indeed, previous stud-
ies using moxiﬂoxacin monotherapy demonstrated good clinical
and bacteriological efﬁcacy without using additional anaerobic
coverage with metronidazole [8–10].
Bacteriological efﬁcacy for both agents was high across the types
and causes of cIAIs against the most common causative organisms,
including the Gram-positive aerobic cocci, Gram-negative rods
and anaerobes. Good bacteriological efﬁcacy was also observed
for the isolated Enterococcus spp. The presence of enterococci is a
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arker of disease, however it has not been proven that its coverage
mproves clinical outcome [22,23]. As recommended, coverage
gainst Enterococcus spp. is not essential in community-acquired
nfections  as enterococci are considered pathogenic in nosocomial
nfections and after previous antibiotic treatment [1]. Whether
overage must be given for enterococci, Pseudomonas aeruginosa,
ther resistant pathogens and Candida spp. depends on local
pidemiological patterns and patient-related factors [24].
A  strength of the PROMISE trial was the wide distribution of
IAI diagnoses highly representative of the patients seen in hos-
itals throughout the study regions. In addition, patients were
rospectively assessed for disease severity using peritonitis sco-
ing systems that are more suitable than APACHE II. Accordingly,
igh scores on both the MPI  and POSSUM scales conﬁrmed that
atients had signiﬁcant peritonitis. There was a high rate of patients
ith microbiologically documented infection; source control and
ccurrence of wound infections were assessed throughout the trial,
ccurately ensuring the clinical situation.
Higher rates of wound infection were seen in the current study
approximately 10% overall) compared with previous studies (typ-
cally 2% in clean wounds) [25]. This may  be due to the use of
tringent criteria set by the US Centers for Disease Control and Pre-
ention [26] to capture infections that were not considered in other
tudies. Most wound infections were superﬁcial and did not require
lternative antibiotic therapy. Furthermore, a high proportion of
pen surgeries (approximately 90%) were carried out in this study;
his is associated with higher rates of wound infection compared
ith laparoscopic surgery [27].
There are a number of clinical conditions where antibiotic treat-
ent should last for <24 h. These conditions represent patients
ith minimal risk for infectious complications. These patients were
xcluded from participation in this study.
This was a Phase III, pivotal study and strict selection criteria
ere used to ensure that the study population would be as homo-
eneous as possible. With the objective of accurate assessment
f the antibiotic effect of the study drugs, all conditions that are
nown to potentially affect outcome were excluded. These condi-
ions are generally listed as exclusion criteria in the published Phase
II studies aimed at evaluating antibiotics in cIAI [12]. Patients who
eemed at baseline to require relaparotomies were excluded on the
asis that a second source control procedure could have blunted the
ffect of the antibiotics, or once their treatment had started it would
ave been difﬁcult to judge whether patients became treatment
ailures requiring second surgery. Patients requiring vasopressors
t baseline were not haemodynamically stable and therefore could
ave developed early complications leading to withdrawal from
he study. Moreover, moxiﬂoxacin is not recommended for these
everely ill patients [1].
Neither  moxiﬂoxacin nor ertapenem demonstrated an unex-
ected AE proﬁle compared with previous studies [8–10,12,13];
oth agents tended to cause mainly gastrointestinal events (nau-
ea and diarrhoea). The difference in AEs between the groups was
enerally driven by post-therapy wound infections and, in part,
xplained by the slightly higher percentage of infections originating
rom the left colon in the moxiﬂoxacin group.
Hepatotoxicity and cardiac toxicity were not observed with
ither moxiﬂoxacin or ertapenem therapy. Hepatic safety is a
otential issue for most antimicrobials [28,29]. Ertapenem does
ot carry either a hepatic or a cardiac safety warning [15].
here have been recent changes to the EU licence of moxi-
oxacin to include a warning about the potential for serious
iver disease [14] and on the arrhythmogenic potential due to
Tc interval prolongation [14,28]. There was no evidence of
ncreased levels of C. difﬁcile-associated disease in PROMISE,
ith only one case of C. difﬁcile colitis in each group. Like
any other broad-spectrum antimicrobials, both moxiﬂoxacin andntimicrobial Agents 41 (2013) 57– 64 63
ertapenem have been associated with C. difﬁcile-associated disease
[14,15,30].
In summary, PROMISE showed that, when used according
to prescribing guidelines, moxiﬂoxacin is a suitable once-daily
therapy for the treatment of cIAIs in patients with mild-to-
moderate community-acquired infections.
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